Prevalence and related factors of sarcopenia in newly diagnosed cancer patients


Oflazoglu U., ALACACIOĞLU A., Varol U., KÜÇÜKZEYBEK Y., Salman T., Taskaynatan H., ...More

SUPPORTIVE CARE IN CANCER, vol.28, no.2, pp.837-843, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 2
  • Publication Date: 2020
  • Doi Number: 10.1007/s00520-019-04880-4
  • Journal Name: SUPPORTIVE CARE IN CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.837-843
  • Keywords: Sarcopenia, Prevalence, Bioelectric impedance analysis, Body composition measurement, Advanced age, SKELETAL-MUSCLE MASS, BIOELECTRICAL-IMPEDANCE ANALYSIS, PHYSICAL PERFORMANCE, BODY-COMPOSITION, SOLID TUMORS, OLDER MEN, EPIDEMIOLOGY, DISABILITY, PREDICTION, CONSENSUS
  • Dokuz Eylül University Affiliated: Yes

Abstract

Introduction Sarcopenia is defined as the loss of muscle mass and muscular functioning. Although sarcopenia prevalence is highly variable in the literature, pre-chemotherapy sarcopenia prevalence was not well studied in newly diagnosed cancer patients. In this context, the present study aims to determine the prevalence of sarcopenia and its related factors in this population. Material and methods Prospectively, newly diagnosed cancer patients were evaluated for body composition measurement and muscle strength by employing the bioelectric impedance analysis method and handgrip dynamometer tool. Results A total of 461 patients were included in the study. The median age of patients was 59 years (range 18-83) and 258 patients (56%) were women. Sarcopenia was present in 77 patients (16.7%) and was at significantly higher frequencies in men (p = 0.015), advanced age (>= 65 years, p = 0.014), lower body mass index (BMI < 25, p = < 0.001), and poor performance status (ECOG status > 0, p = 0.026). In multivariate analyses, advanced age (over 65 years), gender (men), and lower body mass index (BMI < 25) were significantly associated with sarcopenia (p values 0.033, < 0.001, and < 0.001, respectively). Conclusions Our study is the first prevalence study conducted with bioelectric impedance analysis on Turkish cancer patients and sarcopenia was detected to be notably prevalent among our patients with newly diagnosed cancer. Given the likely negative outcomes of sarcopenia reported in the literature (treatment failure, increased complications, and impaired survival), it is important to know the presence of sarcopenia before treatment and take preventive precautions.